Compare Inovio Pharmaceuticals Inc (INO) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Wheaton Precious Metals Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Wheaton Precious Metals Corp trades at $107.25 (market cap $46.54B). The key difference: Wheaton Precious Metals Corp is far larger — about 521.3× Inovio Pharmaceuticals Inc's market cap, and Wheaton Precious Metals Corp pays a 0.75% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | WPM | |
|---|---|---|
Market Cap | $89.27M | $46.54B |
Sector | Health | Basic Materials |
52-Week High | $2.87 | $165.72 |
52-Week Low | $1.05 | $91.00 |
Enterprise Value | $60.28M | $44.39B |
Dividend Yield | — | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Wheaton Precious Metals (WPM) trades at $103.81, down 0.36% today, with a bearish technical signal and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.28 exceeding the $1.24 estimate. Revenue surged to $2.31 billion in 2025, driving a net income margin of 63.58%. Operating cash flow reached a record $1.90 billion, supporting a positive net cash flow of $335.43 million. Analyst consensus remains strongly bullish with an 80% buy rating and a $161.75 price target, indicating significant upside potential.
WPM presents a compelling investment case based on robust fundamentals and strong analyst support, though technical indicators suggest near-term caution. Key opportunities include sustained earnings growth, high profit margins, and a solid cash flow outlook. Risks involve exposure to precious metal price volatility, geopolitical tensions impacting mining operations, and potential valuation compression if silver prices remain subdued. The stock's current price offers an attractive entry point relative to analyst targets, but investors should monitor commodity market trends and quarterly performance closely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
